An experimental Parkinson’s drug missed its major objective in a mid-stage trial, Roche mentioned, in what’s the second setback this week for candidate therapies for the neurodegenerative situation.
in Business
Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study
